Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer (RNA-Seq)
RNA-seq (gene expression) · human · 32 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 32 samples: 15 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancerNature genetics · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE255133_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1073579 and SRA study SRP488343. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 30 samples.
How we read this: 15 replicated groups read from 32 sample titles; they account for 30 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8064594 VCaP_DMSO_rep1 VCaP_DMSO
- GSM8064595 VCaP_DMSO_rep2 VCaP_DMSO
- GSM8064596 VCaP_CBPD_4h_rep1 VCaP_CBPD_4h
- GSM8064597 VCaP_CBPD_4h_rep2 VCaP_CBPD_4h
- GSM8064598 VCaP_GNE_4h_rep1 VCaP_GNE_4h
- GSM8064599 VCaP_GNE_4h_rep2 VCaP_GNE_4h
- GSM8064600 VCaP_CCS_4h_rep1 VCaP_CCS_4h
- GSM8064601 VCaP_CCS_4h_rep2 VCaP_CCS_4h
- GSM8064602 VCaP_CBPD_24h_rep1 VCaP_CBPD_24h
- GSM8064603 VCaP_CBPD_24h_rep2 VCaP_CBPD_24h
- GSM8064604 VCaP_GNE_24h_rep1 VCaP_GNE_24h
- GSM8064605 VCaP_GNE_24h_rep2 VCaP_GNE_24h
- GSM8064606 VCaP_CCS_24h_rep1 VCaP_CCS_24h
- GSM8064607 VCaP_CCS_24h_rep2 VCaP_CCS_24h
- GSM8064608 LNCaP_CSS_medium__rep1 LNCaP_CSS_medium
- GSM8064609 LNCaP_CSS_medium__rep2 LNCaP_CSS_medium
- GSM8064610 LNCaP_CD_medium_CBPD_12h_rep1 LNCaP_CD_medium_CBPD_12h
- GSM8064611 LNCaP_CD_medium_CBPD_12h_rep2 LNCaP_CD_medium_CBPD_12h
- GSM8064612 LNCaP_CD_medium_GNE_12h_rep1 LNCaP_CD_medium_GNE_12h
- GSM8064613 LNCaP_CD_medium_GNE_12h_rep2 LNCaP_CD_medium_GNE_12h
- GSM8064614 LNCaP_R1881_rep1 LNCaP_R1881
- GSM8064615 LNCaP_R1881_rep2 LNCaP_R1881
- GSM8064616 LNCaP_R1881_CBPD_12h_rep1 LNCaP_R1881_CBPD_12h
- GSM8064617 LNCaP_R1881_CBPD_12h_rep2 LNCaP_R1881_CBPD_12h
- GSM8064618 LNCaP_R1881_GNE_12h_rep1 LNCaP_R1881_GNE_12h
- GSM8064619 LNCaP_R1881_GNE_12h_rep2 LNCaP_R1881_GNE_12h
- GSM8064620 VCaP_EUseq_DMSO_rep1 VCaP_EUseq_DMSO
- GSM8064621 VCaP_EUseq_DMSO_rep2 VCaP_EUseq_DMSO
- GSM8064622 VCaP_Euseq_100nM_CBPD_2h_rep1
- GSM8064623 VCaP_EUseq_100nM_CBPD_2h_rep2
- GSM8064624 VCaP_EUseq_100nM_CBPD_4h_rep1 VCaP_EUseq_100nM_CBPD_4h
- GSM8064625 VCaP_EUseq_100nM_CBPD_4h_rep2 VCaP_EUseq_100nM_CBPD_4h
- GSE255134 Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer 76 samples shares p300, h2b, cbp, enhanceosomes, degradation, acetylated, targeting, prostate
- GSE255132 Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer (ChIP-Seq) 38 samples shares p300, h2b, cbp, enhanceosomes, degradation, acetylated, targeting, prostate
- GSE296237 Targeting p300/CBP abolishes HOXB13 loss-induced lipogenesis and tumor metastasis [RNA-seq] 28 samples shares p300, cbp, targeting
- GSE275778 AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer [RNA-seq: 22RV1] 20 samples shares p300, cbp, prostate
- GSE291279 Therapeutic Targeting of the p300/CBP Bromodomain Enhances the Efficacy of Immune Checkpoint Blockade Therapy 6 samples shares p300, cbp, targeting
- GSE237043 Targeting Dependency on a Paralog Pair of CBP/p300 against De-repression of KREMEN2 in SMARCB1-Deficient Cancers 60 samples shares p300, cbp, targeting
- GSE296250 Targeting p300/CBP abolishes HOXB13 loss-induced lipogenesis and tumor metastasis 43 samples shares p300, cbp, targeting
- GSE296236 Targeting p300/CBP abolishes HOXB13 loss-induced lipogenesis and tumor metastasis [ChIP-seq] 15 samples shares p300, cbp, targeting
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.